Collaborating for a cure

Collaborating for a cure

Calvary Mater Newcastle and local charity Hope4Cure Foundation have joined forces this Ovarian Cancer Awareness month, to support women and their families experiencing ovarian and gynaecological cancer in the Hunter region.

Following a $40,000 donation from Hope4Cure Foundation, Calvary Mater Newcastle launched a special research grant for its researchers to help bolster research in ovarian and gynaecological cancer.

Dr Jennette Sakoff, Chief Hospital Scientist, Medical Oncology, Calvary Mater Newcastle, and her collaborator, Prof Janice Aldrich-Wright from Western Sydney University, are the recipients of the inaugural Hope4Cure Grant Fund. The funds will go towards a project to pursue the development of new platinum-based molecules for the treatment of ovarian cancer.

Dr Jennette Sakoff explains, “Platinum-based compounds have been used for the treatment of cancer since the 1960’s. These agents kill cancer cells by binding to DNA. However, they do have side-effects such as kidney and nerve toxicity, and cancers do become resistant to their use over time. To overcome these problems we need to discover agents that function differently and which only target the cancer cells and not healthy cells.

“The team has discovered a unique class of platinum-based compounds that are different to the standard platinum-based intravenous chemotherapy treatments such as cisplatin, carboplatin or oxaliplatin. These compounds are very selective at targeting ovarian cancer cells. Indeed, they are 1,000 times more potent at killing ovarian cancer cells grown in the laboratory compared with non-cancer cells and cells derived from other tumour types. The funds will be used to understand why this occurs and how can we exploit this for the development of better treatments for ovarian cancer.”

Sarah Frith, Co-Founder, Hope4Cure Foundation, said, “We are so pleased to be able to support local researchers make advancements in ovarian and gynaecological cancer. We are fortunate to have the unwavering support of the local community, who have supported our fundraisers. Last year, 100 per cent of the funds raised from our Christmas in July event has contributed to the Hope4Cure Grant Fund, totalling $40,000. We’d like to offer our sincere gratitude to the attendees at the event, the wonderful businesses who supported by providing prizes and auction items, and to everyone who made the night a huge success and have enabled this important grant to be established.”

Ovarian cancer has the lowest survival rate of any women’s cancer. Each day in Australia, four women are diagnosed with the disease and three will die. One in 10 Australians know someone who has been diagnosed with ovarian cancer.

Calvary Mater Newcastle and local charity Hope4Cure Foundation have joined forces this Ovarian Cancer Awareness month, to support women and their families experiencing ovarian and gynaecological cancer in the Hunter region.

Following a $40,000 donation from Hope4Cure Foundation, Calvary Mater Newcastle launched a special research grant for its researchers to help bolster research in ovarian and gynaecological cancer.

Dr Jennette Sakoff, Chief Hospital Scientist, Medical Oncology, Calvary Mater Newcastle, and her collaborator, Prof Janice Aldrich-Wright from Western Sydney University, are the recipients of the inaugural Hope4Cure Grant Fund. The funds will go towards a project to pursue the development of new platinum-based molecules for the treatment of ovarian cancer.

Dr Jennette Sakoff explains, “Platinum-based compounds have been used for the treatment of cancer since the 1960’s. These agents kill cancer cells by binding to DNA. However, they do have side-effects such as kidney and nerve toxicity, and cancers do become resistant to their use over time. To overcome these problems we need to discover agents that function differently and which only target the cancer cells and not healthy cells.

“The team has discovered a unique class of platinum-based compounds that are different to the standard platinum-based intravenous chemotherapy treatments such as cisplatin, carboplatin or oxaliplatin. These compounds are very selective at targeting ovarian cancer cells. Indeed, they are 1,000 times more potent at killing ovarian cancer cells grown in the laboratory compared with non-cancer cells and cells derived from other tumour types. The funds will be used to understand why this occurs and how can we exploit this for the development of better treatments for ovarian cancer.”

Sarah Frith, Co-Founder, Hope4Cure Foundation, said, “We are so pleased to be able to support local researchers make advancements in ovarian and gynaecological cancer. We are fortunate to have the unwavering support of the local community, who have supported our fundraisers. Last year, 100 per cent of the funds raised from our Christmas in July event has contributed to the Hope4Cure Grant Fund, totalling $40,000. We’d like to offer our sincere gratitude to the attendees at the event, the wonderful businesses who supported by providing prizes and auction items, and to everyone who made the night a huge success and have enabled this important grant to be established.”

Ovarian cancer has the lowest survival rate of any women’s cancer. Each day in Australia, four women are diagnosed with the disease and three will die. One in 10 Australians know someone who has been diagnosed with ovarian cancer.

Support Us.
Support You.

Find Out How